Gauri D Kelekar, MD
Hematology/Oncology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 5
Offices
5 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Looking this up.
Hospitals listed: 057003 · California Pacific Medical Center - Mission Bernal · California Pacific Medical Center- Van Ness Campus · California Pacific Medical Ctr-Davies Campus Hosp · Mills-Peninsula Medical Center · Novato Community Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Kelekar’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A111323 · Current
Licensed to practise in California · since 2010 · expires 2028-03-31 · Drexel University College of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
5 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- California Pacific Medical Center - Mission BernalSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Church · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.322, Oct 2024 – Sep 2025
- California Pacific Medical Center- Van Ness CampusSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.224, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.325, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.373, Oct 2024 – Sep 2025
- California Pacific Medical Ctr-Davies Campus HospSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · No emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 3 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.187, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
- Peninsula Medical CenterBurlingame, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 78% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.139, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.242, Oct 2024 – Sep 2025
See every measure and the patient survey for California Pacific Medical Center - Mission Bernal
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 3 the same, 3 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.322 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.19 to 2.28) · 336 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.87 (0.47 to 1.27) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 163.19 (101.27 to 225.11) · 28 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.6 · 155 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.4 · 177 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 32 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.2 · 1,281 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.19 (0 to 0.42) · 2,912 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.24 (0.04 to 0.45) · 2,681 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.07 (1.81 to 6.33) · 787 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.61 (0 to 3.31) · 425 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.46 (0.79 to 4.12) · 755 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.36 (0 to 16.38) · 431 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.47 (1.38 to 9.55) · 401 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.7 (0.2 to 3.2) · 105 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 1.16) · 2,291 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 2.4 · 369 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.602 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.618 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 242 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 20.9 · 197 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 39.6 · 203 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 292 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 353 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.9 · 74 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.4) · 110 cases | No different | Jan 2024 – Dec 2024 |
What patients said (406 patients answered, 18% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 60% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 74% |
| Staff "always" explained new medications | 74% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 47% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for California Pacific Medical Center- Van Ness Campus
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 8 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.224 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.325 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.373 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.14 (0.3 to 1.97) · 2,271 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.81 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 192.86 (151.51 to 234.22) · 140 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.6 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.3 · 60 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.5 · 143 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 356 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.3 · 259 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 173 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,316 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.31 (0.12 to 0.49) · 6,430 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.09 to 0.47) · 7,168 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.3 (1.5 to 5.09) · 2,196 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 2.47 (1.21 to 3.74) · 925 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.63 (1.37 to 3.88) · 1,954 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.13 (6.06 to 14.2) · 1,112 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.26 (4.67 to 9.85) · 1,084 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.31 to 3.03) · 832 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 0.85) · 5,406 cases | No different | Jul 2022 – Jun 2024 |
| MRSA BacteremiaInfections | 0.443 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.717 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 200 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.3 · 449 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 18.2 · 187 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 8.7 · 418 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 7.1 · 260 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19.2 · 293 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (3.6 to 7.6) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.2 (7.7 to 13.5) · 157 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for CABGUnplanned return visits | 11 · 33 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.2 · 66 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.4 to 16.7) · 551 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.3) · 219 cases | No different | Jan 2024 – Dec 2024 |
What patients said (478 patients answered, 20% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 77% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 70% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for California Pacific Medical Ctr-Davies Campus Hosp
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 4 the same, 1 worse of 5 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.187 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.02 (0 to 2.09) · 232 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.98 (0.56 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 10 · 72 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.1 · 106 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.4 · 257 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 721 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.03 to 0.49) · 2,031 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.45) · 2,032 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.35 (0.94 to 5.76) · 419 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 211 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.84 (1.24 to 4.44) · 414 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 11.95 (2.91 to 20.98) · 218 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.61 (1.47 to 9.75) · 198 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.74 (0.22 to 3.26) · 52 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.32 (0 to 1.28) · 1,461 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.6 · 58 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.756 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22.1 · 91 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 65.3 · 84 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -26.6 · 115 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.4 · 142 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.5 · 55 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 25 cases | None | Jul 2023 – Jun 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 312 cases | No different | Jan 2024 – Dec 2024 |
What patients said (602 patients answered, 22% of those asked)
| Cleanliness | 4 |
| Nurse communication | 2 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 59% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 73% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 71% |
| Nurses "always" treated them with courtesy and respect | 81% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
See every measure and the patient survey for Peninsula Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 0 better, 10 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.139 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.242 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.21 (0.27 to 2.15) · 1,258 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.81 (0.51 to 1.1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 155.44 (112.67 to 198.21) · 90 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.5 · 32 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 82 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 188 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9 · 473 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.8 · 342 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.4 · 485 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 3,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.4) · 6,904 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.4) · 7,052 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.41 (1.43 to 5.39) · 1,695 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.72 (0.17 to 3.28) · 665 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.11 (0.66 to 3.56) · 1,545 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.1 (1.3 to 12.9) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.96 (2.63 to 9.29) · 653 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.15 to 3.08) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.14 (0 to 0.78) · 5,539 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.7 · 192 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.215 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.263 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.74 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.3 · 300 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19 · 702 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 1.2 · 207 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13.6 · 531 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 24.3 · 343 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.1 · 449 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 4.5 (2.8 to 7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 9.6 (6.7 to 13.7) · 85 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.7 · 189 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 11 · 45 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.6 · 117 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.7 to 17.2) · 584 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 764 cases | No different | Jan 2024 – Dec 2024 |
What patients said (523 patients answered, 27% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 76% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 78% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$327,595
Medicare paid this office $327,595 for 545 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 189 | $99,679 | $170 |
| Return visit (30+ min) | 374 | $72,246 | $114 |
| New patient visit (60+ min) | 106 | $21,553 | $203 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 11 | $13,126 | $6 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $10,620 | $105 |
See all 10 services
| Long return visit (40+ min) | 189 | $99,679 | $170 |
| Return visit (30+ min) | 374 | $72,246 | $114 |
| New patient visit (60+ min) | 106 | $21,553 | $203 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 11 | $13,126 | $6 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $10,620 | $105 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 63 | $10,487 | $154 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 254 | $6,259 | $8 |
| Insertion of needle into vein for collection of blood sample | 201 | $3,782 | $9 |
| New patient visit (60+ min) | 22 | $3,570 | $162 |
| Injection of drug or substance under skin or into muscle | 26 | $1,964 | $14 |
Who their Medicare patients are
545 Original Medicare patients in 2024. Average age 75 · Under 65 7% · 85 and older 13% · Women 50% · Also on Medicaid 23% · Health risk score 1.71. At or below the middle of the specialty; the typical hematology-oncology clinician is at 2.04.
Conditions among them: High blood pressure 72% · Chronic kidney disease 35% · Diabetes 30% · Coronary heart disease 26% · Cancer 26% · Depression 19% · Atrial fibrillation 18% · Heart failure 17% · COPD 12% · Dementia 8% · Stroke 8%.
The office billed $1,094,314, Medicare allowed $416,687 and paid $327,595; for 14,682 services of 38 kinds; $93,529 of it was for drugs given in the office and $234,066 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 545 | 14,682 | 75 | 1.71 | $1,094,314 | $327,595 |
| 2023 | 519 | 14,124 | 75 | 1.85 | $1,028,982 | $292,786 |
| 2022 | 464 | 14,828 | 74 | 1.80 | $1,380,228 | $434,242 |
| 2021 | 445 | 25,749 | 74 | 1.92 | $1,660,566 | $509,925 |
| 2020 | 403 | 32,515 | 74 | 1.97 | $1,355,112 | $381,623 |
| 2019 | 398 | 55,067 | 74 | 2.10 | $4,112,145 | $1,343,135 |
| 2018 | 322 | 38,942 | 74 | 1.99 | $4,282,377 | $1,306,386 |
| 2017 | 287 | 22,428 | 74 | 2.08 | $2,392,630 | $764,221 |
| 2016 | 40 | 1,165 | 70 | 2.00 | $103,781 | $38,047 |
| 2015 | 17 | 30 | 63 | 3.97 | $14,178 | $2,812 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 12 services
| Return visit (30+ min) | 380 | $91,501 | $115 |
| Long return visit (40+ min) | 138 | $49,669 | $168 |
| New patient visit (60+ min) | 129 | $26,184 | $203 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 11 | $22,033 | $6 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $12,497 | $108 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $11,510 | $156 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 225 | $6,678 | $8 |
| Collection of blood sample from implanted device | 51 | $5,356 | $28 |
| Injection of drug or substance into vein | 43 | $4,567 | $35 |
| Insertion of needle into vein for collection of blood sample | 185 | $4,143 | $8 |
| Injection of drug or substance under skin or into muscle | 27 | $2,536 | $14 |
| Infusion, normal saline solution, 250 cc | 27 | $23 | None |
2022: 12 services
| Return visit (30+ min) | 337 | $86,650 | $116 |
| Long return visit (40+ min) | 159 | $65,567 | $168 |
| New patient visit (60+ min) | 111 | $22,005 | $198 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 16 | $13,405 | $6 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 68 | $12,979 | $178 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 54 | $11,426 | $91 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 202 | $5,481 | $8 |
| Injection of drug or substance into vein | 37 | $4,660 | $41 |
| Collection of blood sample from implanted device | 42 | $3,056 | $28 |
| Injection of drug or substance under skin or into muscle | 42 | $2,554 | $14 |
| Insertion of needle into vein for collection of blood sample | 162 | $1,288 | $3 |
| Infusion, normal saline solution, 250 cc | 11 | $6 | None |
2021: 10 services
| Return visit (30+ min) | 335 | $116,433 | $117 |
| Long return visit (40+ min) | 125 | $46,536 | $164 |
| Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 20 | $22,457 | $7 |
| New patient visit (60+ min) | 109 | $21,711 | $199 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 95 | $19,737 | $179 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 62 | $12,513 | $93 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 188 | $6,309 | $8 |
| Injection of drug or substance under skin or into muscle | 43 | $3,775 | $14 |
| Collection of blood sample from implanted device | 39 | $2,205 | $28 |
| Insertion of needle into vein for collection of blood sample | 143 | $1,167 | $3 |
2020: 13 services
| Return visit (30+ min) | 287 | $85,993 | $97 |
| Long return visit (40+ min) | 94 | $24,952 | $135 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 90 | $19,103 | $182 |
| New patient visit (60+ min) | 93 | $17,531 | $189 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $12,043 | $96 |
| Injection of drug or substance under skin or into muscle | 35 | $2,798 | $14 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 98 | $2,238 | $8 |
| Telephone medical discussion with physician, 21-30 minutes | 11 | $1,150 | $105 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 22 | $1,090 | $44 |
| Influenza vaccine split virus, preservative free | 11 | $671 | $61 |
| Insertion of needle into vein for collection of blood sample | 70 | $525 | $3 |
| Collection of blood sample from implanted device | 11 | $396 | $26 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 12 | $156 | None |
2019: 15 services
| Return visit (30+ min) | 244 | $75,234 | $100 |
| Administration of chemotherapy into vein, 1 hour or less | 23 | $22,098 | $147 |
| New patient visit (60+ min) | 119 | $21,790 | $183 |
| Long return visit (40+ min) | 82 | $18,654 | $134 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 82 | $17,904 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 78 | $17,641 | $93 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 39 | $11,920 | $72 |
| Injection of drug or substance under skin or into muscle | 41 | $3,584 | $16 |
| Injection of additional new drug or substance into vein | 21 | $2,882 | $17 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 12 | $1,837 | $32 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 35 | $1,831 | None |
| Short return visit (20+ min) | 17 | $1,205 | $63 |
| Injection of drug or substance into vein | 11 | $642 | $40 |
| Injection, ondansetron hydrochloride, per 1 mg | 16 | $128 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $77 | None |
2018: 18 services
| Return visit (30+ min) | 182 | $65,323 | $97 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 84 | $25,796 | $92 |
| Administration of chemotherapy into vein, 1 hour or less | 23 | $20,372 | $143 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 87 | $17,000 | $179 |
| Long return visit (40+ min) | 79 | $14,871 | $128 |
| New patient visit (60+ min) | 80 | $14,833 | $185 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 28 | $9,498 | $73 |
| Injection of drug or substance under skin or into muscle | 28 | $3,279 | $20 |
| Injection of additional new drug or substance into vein | 21 | $3,061 | $18 |
| Administration of chemotherapy into vein, each additional hour | 14 | $1,832 | $31 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 29 | $1,565 | None |
| Influenza vaccine split virus, preservative free | 21 | $943 | $43 |
| Short return visit (20+ min) | 11 | $821 | $68 |
| Administration of influenza virus vaccine | 23 | $607 | $25 |
| Insertion of needle into vein for collection of blood sample | 16 | $106 | $3 |
| Injection, dexamethasone sodium phosphate, 1 mg | 17 | $96 | None |
| Injection, ondansetron hydrochloride, per 1 mg | 13 | $93 | None |
| Injection, diphenhydramine hcl, up to 50 mg | 12 | $17 | None |
2017: 13 services
| Return visit (30+ min) | 150 | $38,976 | $99 |
| Long return visit (40+ min) | 122 | $36,349 | $122 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 60 | $17,063 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 76 | $15,980 | $180 |
| New patient visit (60+ min) | 59 | $10,956 | $186 |
| Administration of chemotherapy into vein, 1 hour or less | 15 | $8,079 | $144 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 16 | $4,665 | $71 |
| Injection of drug or substance under skin or into muscle | 29 | $4,583 | $25 |
| Injection of additional new drug or substance into vein | 14 | $2,531 | $23 |
| Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 13 | $930 | None |
| Insertion of needle into vein for collection of blood sample | 95 | $917 | $3 |
| Influenza vaccine split virus, preservative free | 18 | $794 | $44 |
| Administration of influenza virus vaccine | 18 | $583 | $32 |
2016: 1 service
| Long return visit (40+ min) | 13 | $1,909 | $136 |
Medicaid work
$33,471 in 2024
Medicaid paid $33,471 for 715 billed services this clinician did in 2024, up to 34 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 300 | $24,947 |
| Return visit (30+ min) | 135 | $7,250 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 280 | $1,274 |
| 2024 | 715 | 3 | 34 | $33,471 |
| 2023 | 760 | 3 | 32 | $20,205 |
| 2022 | 465 | 3 | 27 | $11,294 |
| 2021 | 356 | 2 | 33 | $9,959 |
| 2020 | 230 | 1 | 33 | $5,008 |
| 2019 | 161 | 1 | 18 | $3,267 |
| 2018 | 70 | 1 | 14 | $844 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 162 | $9,898 |
| Return visit (30+ min) | 291 | $8,886 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 307 | $1,421 |
2022
| Long return visit (40+ min) | 109 | $6,168 |
| Return visit (30+ min) | 199 | $4,631 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 157 | $496 |
2021
| Return visit (30+ min) | 273 | $9,685 |
| Blood count; complete (CBC), automated (Hgb, Hct, RBC, WBC and platelet count) and automated differential WBC count | 83 | $274 |
2020
| Return visit (30+ min) | 230 | $5,008 |
2019
| Return visit (30+ min) | 161 | $3,267 |
2018
| Return visit (30+ min) | 70 | $844 |
Drugs they prescribed that Part D paid
$4,162,894
Pharmacies billed $4,162,894 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 2% of their Part D prescriptions (21 of 1,211) in 2024. At or below the middle of the specialty; the typical hematology-oncology clinician is at 5%.
795 generic and fewer than 11 brand-name prescriptions · $4,162,894 in drug cost · 27 antibiotic prescriptions to 22 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Tagrisso | 24 | $579,005 | $24,125 |
| Lenvima | 21 | $554,374 | $26,399 |
| Brukinsa | 36 | $473,994 | $13,166 |
| Idhifa | 13 | $445,483 | $34,268 |
| Imbruvica | 18 | $295,044 | $16,391 |
See all 32 drugs
| Tagrisso | 24 | $579,005 | $24,125 |
| Lenvima | 21 | $554,374 | $26,399 |
| Brukinsa | 36 | $473,994 | $13,166 |
| Idhifa | 13 | $445,483 | $34,268 |
| Imbruvica | 18 | $295,044 | $16,391 |
| Venclexta | 13 | $200,913 | $15,455 |
| Zytiga | 13 | $147,073 | $11,313 |
| Eliquis | 120 | $124,155 | $1,035 |
| Sandostatin Lar Depot | 14 | $98,106 | $7,008 |
| Imatinib Mesylate | 24 | $70,089 | $2,920 |
| Xarelto | 26 | $35,062 | $1,349 |
| Everolimus | 14 | $24,420 | $1,744 |
| Creon | 25 | $20,196 | $808 |
| Abiraterone Acetate | 13 | $14,821 | $1,140 |
| Entecavir | 14 | $4,450 | $318 |
| Ondansetron | 62 | $2,907 | $47 |
| Hydroxyurea | 55 | $1,999 | $36 |
| Dexlansoprazole Dr | 11 | $1,750 | $159 |
| Dexamethasone | 30 | $1,041 | $35 |
| Prochlorperazine Maleate | 77 | $1,032 | $13 |
| Loperamide | 41 | $837 | $20 |
| Pantoprazole | 51 | $445 | $9 |
| Potassium Chloride | 15 | $444 | $30 |
| Diphenoxylate-Atropine | 32 | $399 | $12 |
| Allopurinol | 16 | $220 | $14 |
| Mirtazapine | 13 | $178 | $14 |
| Famotidine | 15 | $167 | $11 |
| Trazodone | 37 | $153 | $4 |
| Omeprazole | 11 | $150 | $14 |
| Prednisone | 34 | $128 | $4 |
| Amlodipine Besylate | 14 | $114 | $8 |
| Letrozole | 11 | $92 | $8 |
Year by year
| 2024 | 1,211 | 217 | 2% (21) | None | $4,162,894 |
| 2023 | 1,361 | 223 | 1% (14) | None | $5,173,998 |
| 2022 | 1,366 | 221 | 2% (30) | None | $4,467,546 |
| 2021 | 1,206 | 187 | 3% (34) | 33% | $3,051,953 |
| 2020 | 924 | 152 | 2% (21) | 35% | $2,886,760 |
| 2019 | 847 | 151 | 5% (45) | 26% | $2,180,829 |
| 2018 | 915 | 167 | 7% (63) | 15% | $1,084,575 |
| 2017 | 932 | 155 | 14% (132) | None | $1,031,304 |
| 2016 | 121 | 39 | None | 31% | $505,565 |
| 2015 | 32 | 16 | None | 34% | $189,880 |
| 2014 | 110 | 18 | 12% (13) | 23% | $166,881 |
| 2013 | 201 | 24 | 11% (23) | None | $253,654 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 33 drugs
| Lenvima | 63 | $1,537,431 | $24,404 |
| Tagrisso | 25 | $665,960 | $26,638 |
| Idhifa | 12 | $383,209 | $31,934 |
| Venclexta | 19 | $295,636 | $15,560 |
| Brukinsa | 18 | $271,730 | $15,096 |
| Imbruvica | 16 | $254,020 | $15,876 |
| Abiraterone Acetate | 24 | $153,304 | $6,388 |
| Zytiga | 11 | $120,732 | $10,976 |
| Eliquis | 132 | $120,546 | $913 |
| Sandostatin Lar Depot | 15 | $100,018 | $6,668 |
| Bosulif | 12 | $61,910 | $5,159 |
| Imatinib Mesylate | 43 | $53,981 | $1,255 |
| Everolimus | 14 | $43,856 | $3,133 |
| Creon | 30 | $25,507 | $850 |
| Xarelto | 16 | $25,331 | $1,583 |
| Hydroxyurea | 53 | $4,265 | $80 |
| Dexamethasone | 44 | $1,182 | $27 |
| Mirtazapine | 23 | $1,129 | $49 |
| Prochlorperazine Maleate | 77 | $1,045 | $14 |
| Ondansetron | 66 | $1,024 | $16 |
| Pantoprazole | 44 | $729 | $17 |
| Loperamide | 18 | $591 | $33 |
| Prednisone | 58 | $437 | $8 |
| Anastrozole | 11 | $420 | $38 |
| Omeprazole | 17 | $399 | $23 |
| Allopurinol | 21 | $365 | $17 |
| Diphenoxylate-Atropine | 19 | $346 | $18 |
| Acyclovir | 23 | $287 | $12 |
| Amlodipine Besylate | 23 | $240 | $10 |
| Trazodone | 23 | $220 | $10 |
| Potassium Chloride | 14 | $177 | $13 |
| Famotidine | 13 | $167 | $13 |
| Lithium Carbonate Er | 13 | $74 | $6 |
2022: 34 drugs
| Lenvima | 33 | $773,468 | $23,438 |
| Imbruvica | 32 | $485,893 | $15,184 |
| Empaveli | 13 | $474,544 | $36,503 |
| Tagrisso | 14 | $433,301 | $30,950 |
| Calquence | 19 | $275,112 | $14,480 |
| Abiraterone Acetate | 27 | $228,194 | $8,452 |
| Everolimus | 18 | $127,775 | $7,099 |
| Zytiga | 11 | $120,732 | $10,976 |
| Eliquis | 133 | $107,060 | $805 |
| Imatinib Mesylate | 45 | $59,896 | $1,331 |
| Bosulif | 12 | $58,593 | $4,883 |
| Xarelto | 17 | $22,561 | $1,327 |
| Creon | 30 | $20,001 | $667 |
| Hydroxyurea | 70 | $4,406 | $63 |
| Ondansetron | 58 | $3,494 | $60 |
| Dexamethasone | 44 | $1,262 | $29 |
| Prochlorperazine Maleate | 56 | $1,131 | $20 |
| Mirtazapine | 23 | $870 | $38 |
| Pantoprazole | 49 | $787 | $16 |
| Potassium Chloride | 34 | $643 | $19 |
| Acyclovir | 27 | $515 | $19 |
| Prednisone | 54 | $457 | $8 |
| Ondansetron Odt | 12 | $366 | $31 |
| Omeprazole | 17 | $359 | $21 |
| Amlodipine Besylate | 34 | $344 | $10 |
| Anastrozole | 15 | $305 | $20 |
| Allopurinol | 19 | $237 | $12 |
| Loperamide | 14 | $219 | $16 |
| Tamoxifen Citrate | 12 | $205 | $17 |
| Diphenoxylate-Atropine | 12 | $177 | $15 |
| Gabapentin | 11 | $163 | $15 |
| Azithromycin | 21 | $137 | $7 |
| Sulfamethoxazole-Trimethoprim | 11 | $133 | $12 |
| Trazodone | 14 | $125 | $9 |
2021: 30 drugs
| Imbruvica | 64 | $905,121 | $14,143 |
| Lenvima | 20 | $410,264 | $20,513 |
| Nexavar | 21 | $278,310 | $13,253 |
| Sandostatin Lar Depot | 14 | $157,048 | $11,218 |
| Zytiga | 13 | $142,683 | $10,976 |
| Venclexta | 13 | $136,799 | $10,523 |
| Everolimus | 12 | $109,592 | $9,133 |
| Imatinib Mesylate | 30 | $60,031 | $2,001 |
| Procrit | 13 | $44,090 | $3,392 |
| Eliquis | 62 | $41,635 | $672 |
| Xarelto | 27 | $26,110 | $967 |
| Creon | 30 | $17,811 | $594 |
| Hydroxyurea | 66 | $3,524 | $53 |
| Bicalutamide | 11 | $1,520 | $138 |
| Dexamethasone | 40 | $1,090 | $27 |
| Ondansetron | 42 | $1,003 | $24 |
| Prochlorperazine Maleate | 51 | $932 | $18 |
| Anastrozole | 24 | $839 | $35 |
| Potassium Chloride | 36 | $769 | $21 |
| Levetiracetam | 11 | $637 | $58 |
| Pantoprazole | 32 | $603 | $19 |
| Allopurinol | 29 | $453 | $16 |
| Acyclovir | 37 | $389 | $11 |
| Amlodipine Besylate | 37 | $366 | $10 |
| Omeprazole | 36 | $347 | $10 |
| Prednisone | 39 | $281 | $7 |
| Mirtazapine | 12 | $273 | $23 |
| Diphenoxylate-Atropine | 18 | $219 | $12 |
| Tamsulosin | 12 | $202 | $17 |
| Gabapentin | 15 | $134 | $9 |
2020: 24 drugs
| Imbruvica | 56 | $755,737 | $13,495 |
| Tagrisso | 19 | $353,496 | $18,605 |
| Lenvima | 15 | $292,832 | $19,522 |
| Zytiga | 25 | $270,465 | $10,819 |
| Procrit | 16 | $60,781 | $3,799 |
| Imatinib Mesylate | 21 | $58,243 | $2,773 |
| Eliquis | 34 | $22,100 | $650 |
| Xarelto | 20 | $14,058 | $703 |
| Creon | 17 | $8,039 | $473 |
| Hydroxyurea | 67 | $3,889 | $58 |
| Anastrozole | 26 | $997 | $38 |
| Prochlorperazine Maleate | 25 | $996 | $40 |
| Acyclovir | 22 | $582 | $26 |
| Allopurinol | 31 | $548 | $18 |
| Potassium Chloride | 33 | $478 | $14 |
| Dexamethasone | 18 | $476 | $26 |
| Ondansetron | 18 | $363 | $20 |
| Omeprazole | 40 | $361 | $9 |
| Pantoprazole | 21 | $324 | $15 |
| Amlodipine Besylate | 30 | $287 | $10 |
| Prednisone | 34 | $280 | $8 |
| Mirtazapine | 13 | $250 | $19 |
| Trazodone | 12 | $150 | $12 |
| Sulfamethoxazole-Trimethoprim | 14 | $50 | $4 |
2019: 29 drugs
| Tagrisso | 17 | $458,413 | $26,965 |
| Revlimid | 23 | $381,896 | $16,604 |
| Lenvima | 16 | $295,988 | $18,499 |
| Imbruvica | 22 | $267,970 | $12,180 |
| Zytiga | 11 | $122,715 | $11,156 |
| Sandostatin Lar Depot | 12 | $82,147 | $6,846 |
| Imatinib Mesylate | 18 | $71,679 | $3,982 |
| Sprycel | 12 | $46,044 | $3,837 |
| Procrit | 12 | $44,641 | $3,720 |
| Eliquis | 21 | $13,819 | $658 |
| Hydroxyurea | 54 | $2,749 | $51 |
| Anastrozole | 31 | $1,041 | $34 |
| Tamoxifen Citrate | 13 | $744 | $57 |
| Mirtazapine | 28 | $717 | $26 |
| Prochlorperazine Maleate | 31 | $684 | $22 |
| Dexamethasone | 20 | $630 | $31 |
| Ondansetron | 22 | $489 | $22 |
| Allopurinol | 23 | $386 | $17 |
| Pantoprazole | 19 | $356 | $19 |
| Prednisone | 32 | $350 | $11 |
| Omeprazole | 16 | $276 | $17 |
| Acyclovir | 17 | $265 | $16 |
| Amlodipine Besylate | 30 | $262 | $9 |
| Trazodone | 11 | $229 | $21 |
| Metoprolol | 11 | $203 | $18 |
| Potassium Chloride | 14 | $115 | $8 |
| Azithromycin | 12 | $87 | $7 |
| Tramadol | 22 | $81 | $4 |
| Lorazepam | 11 | $52 | $5 |
2018: 26 drugs
| Jakafi | 12 | $164,986 | $13,749 |
| Imatinib Mesylate | 16 | $124,534 | $7,783 |
| Zytiga | 12 | $122,656 | $10,221 |
| Procrit | 16 | $59,444 | $3,715 |
| Hydroxyurea | 51 | $2,937 | $58 |
| Anastrozole | 44 | $1,238 | $28 |
| Tamoxifen Citrate | 18 | $987 | $55 |
| Dexamethasone | 31 | $740 | $24 |
| Ondansetron | 37 | $702 | $19 |
| Prochlorperazine Maleate | 68 | $691 | $10 |
| Bicalutamide | 12 | $683 | $57 |
| Bupropion Hcl Sr | 15 | $608 | $41 |
| Pantoprazole | 17 | $445 | $26 |
| Mirtazapine | 23 | $402 | $17 |
| Levothyroxine | 15 | $369 | $25 |
| Letrozole | 18 | $362 | $20 |
| Polyethylene Glycol 3350 | 29 | $354 | $12 |
| Omeprazole | 21 | $254 | $12 |
| Hydrocodone-Acetaminophen | 16 | $245 | $15 |
| Prednisone | 21 | $220 | $10 |
| Loperamide | 11 | $216 | $20 |
| Amlodipine Besylate | 30 | $214 | $7 |
| Allopurinol | 15 | $201 | $13 |
| Tramadol | 24 | $130 | $5 |
| Lorazepam | 23 | $74 | $3 |
| Trazodone | 13 | $68 | $5 |
2017: 31 drugs
| Xtandi | 26 | $237,566 | $9,137 |
| Zytiga | 11 | $102,737 | $9,340 |
| Tarceva | 13 | $102,242 | $7,865 |
| Imatinib Mesylate | 12 | $98,395 | $8,200 |
| Revlimid | 12 | $62,103 | $5,175 |
| Procrit | 13 | $30,195 | $2,323 |
| Entecavir | 14 | $12,918 | $923 |
| Morphine Sulfate Er | 42 | $2,043 | $49 |
| Hydroxyurea | 32 | $2,006 | $63 |
| Ventolin Hfa | 13 | $1,270 | $98 |
| Anastrozole | 42 | $1,236 | $29 |
| Tamoxifen Citrate | 21 | $1,105 | $53 |
| Ondansetron | 40 | $998 | $25 |
| Dexamethasone | 31 | $553 | $18 |
| Oxycodone | 31 | $545 | $18 |
| Prochlorperazine Maleate | 48 | $385 | $8 |
| Hydrocodone-Acetaminophen | 22 | $294 | $13 |
| Letrozole | 19 | $209 | $11 |
| Mirtazapine | 11 | $185 | $17 |
| Polyethylene Glycol 3350 | 19 | $183 | $10 |
| Loperamide | 11 | $182 | $17 |
| Omeprazole | 13 | $175 | $13 |
| Pantoprazole | 13 | $161 | $12 |
| Lorazepam | 37 | $156 | $4 |
| Gabapentin | 11 | $108 | $10 |
| Tramadol | 27 | $100 | $4 |
| Prednisone | 14 | $90 | $6 |
| Metoclopramide | 15 | $83 | $6 |
| Trazodone | 18 | $72 | $4 |
| Azithromycin | 12 | $71 | $6 |
| Amlodipine Besylate | 11 | $69 | $6 |
2016: 1 drug
| Hydroxyurea | 12 | $134 | $11 |
2014: 3 drugs
| Exemestane | 13 | $4,849 | $373 |
| Omeprazole | 15 | $296 | $20 |
| Hydrocodone-Acetaminophen | 12 | $141 | $12 |
2013: 3 drugs
| Tasigna | 11 | $91,035 | $8,276 |
| Omeprazole | 14 | $290 | $21 |
| Hydromorphone | 11 | $126 | $11 |
Money from drug and device companies
$202 in 2025
| 2025 | 7 | 8 | None | $202 |
| 2024 | 15 | 21 | None | $511 |
| 2023 | 5 | 7 | None | $191 |
| 2022 | 3 | 5 | None | $103 |
| 2021 | 1 | 11 | None | $234 |
| 2020 | 2 | 3 | None | $55 |
| 2019 | 8 | 14 | None | $290 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Array Biopharma | Xalkori | $51 | 2 payments
|
| Adc Therapeutics America | Zynlonta | $34 | 1 payment
|
| Intera Oncology | Intera | $32 | 1 payment
|
| Abbvie | Epkinly | $28 | 1 payment
|
| Janssen Biotech | Tecvayli | $24 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $20 | 1 payment
|
See all 8 published payments
| Adc Therapeutics America | Meals · 2025-12-02 | Zynlonta | $34 |
| Intera Oncology | Meals · 2025-10-23 | Intera | $32 |
| Array Biopharma | Meals · 2025-07-29 | Braftovi | $24 |
| Abbvie | Meals · 2025-03-19 | Epkinly | $28 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-02-18 | Opdivo | $14 |
| Array Biopharma | Meals · 2025-02-11 | Xalkori | $27 |
| Janssen Biotech | Meals · 2025-02-04 | Tecvayli | $24 |
| Deciphera Pharmaceuticals | Meals · 2025-01-28 | Qinlock | $20 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $511
| Pfizer | Bosulif | $76 | 3 payments
|
| Novartis Pharmaceuticals | Kisqali | $59 | 2 payments
|
| Daiichi Sankyo | Enhertu | $45 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Lynparza | $39 | 2 payments
|
| Array Biopharma | Lorbrena | $34 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $34 | 1 payment
|
| Ipsen Biopharmaceuticals | Onivyde | $33 | 1 payment
|
| Celgene | Reblozyl | $28 | 2 payments
|
| Abbvie | Epkinly | $28 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Fruzaqla | $27 | 1 payment
|
| Tempus AI | None | $27 | 1 payment
|
| Regeneron Healthcare Solutions | Libtayo | $25 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $20 | 1 payment
|
| Coherus Biosciences | Udenyca | $19 | 1 payment
|
| Eisai | Lenvima | $18 | 1 payment
|
2023: $191
| Gilead Sciences | Trodelvy | $75 | 1 payment
|
| Eisai | Lenvima | $41 | 3 payments
|
| Merck Sharp & Dohme | Keytruda | $33 | 1 payment
|
| Lilly USA | Verzenio | $29 | 1 payment
|
| Pfizer | Inlyta | $13 | 1 payment
|
2022: $103
| Pfizer | Ibrance | $76 | 3 payments
|
| Janssen Biotech | Imbruvica | $14 | 1 payment
|
| Eisai | Lenvima | $13 | 1 payment
|
2021: $234
| Pfizer | Inlyta | $234 | 11 payments
|
2020: $55
| E.R. Squibb & Sons L.L.C. | None | $41 | 2 payments
|
| Pfizer | Inlyta | $13 | 1 payment
|
2019: $290
| Celgene | Abraxane | $95 | 4 payments
|
| Alexion Pharmaceuticals | Soliris | $48 | 2 payments
|
| Lilly USA | Alimta | $37 | 2 payments
|
| Janssen Biotech | Darzalex | $35 | 2 payments
|
| AbbVie | Venclexta | $23 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | None | $21 | 1 payment
|
| Genentech USA | Venclexta | $18 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $13 | 1 payment
|
Professional record
- NPI
- 1922250323
- Licence
- CA A111323, CA DEA001250California A111323: Current · expires 2028-03-31
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RH0003X (207RH0003X); Internal medicine (207R00000X)
- Mailing address
- 3838 California St, #707, San Francisco, CA, 94118
- NPI first listed
- 2008-10-16
- NPI last updated
- 2017-04-24
This is when the NPI record was last certified, not a medical board exam.